Вы находитесь на странице: 1из 2

NEWS RELEASE

Contact:
Bridget Hall, Communications Manager
Fujifilm Diosynth Biotechnologies
Tel : +44 (0)1642 367320
Cell: +44 (0)7796 938929
Email : bridget.hall@fujifilmdb.com
BIO : Booth # 1467

FUJIFILM DIOSYNTH BIOTECHNOLOGIES COMMISSIONS NEW CELL


BANKING FACILITY AT BILLINGHAM, UK SITE

Billingham, UK/Morrisville, NC, USA : 22nd April 2013 - Fujifilm Diosynth


Biotechnologies has announced that it has commissioned on time its new
mammalian cGMP Cell Banking Facility (CBF) at its Billingham, UK site.

The new CBF is available to the companys customers either as part of a larger
development and manufacturing programme, or as a stand-alone service. It forms
the second stage of a major expansion of the companys mammalian cell culture
capabilities at the site, following installation last year of new process development
and scale-up capabilities. The asset will support delivery of manufacturing
programmes for both Fujifilm Diosynth Biotechnologies Billingham UK, and
Research Triangle Park, North Carolina, USA facilities.

The next stage of the companys expansion will be the commissioning of a new
cGMP manufacturing facility, also in Billingham, which is well under construction, and
due on-line in early Q4 2013. This manufacturing facility, which will primarily utilise
single-use technologies, has been designed with input from regulatory authorities
and key customers, to offer high flexibility for meeting customers needs and setting
new standards. It will initially offer 200L and 1000L single-use bioreactors, with
2000L bioreactors already planned for 2014.

Steve Bagshaw, Managing Director, Fujifilm Diosynth Biotechnologies UK, said I am


delighted that we have commissioned the Cell Bank Facility within a year of its
commencement, and have already started work on our first customer programme.
This is the next step in our strategy to grow our services in the CDMO field,
becoming a world-class player across both microbial and mammalian cell culture
platforms, offering a full life cycle support for our customers.

Fujifilm Diosynth Biotechnologies will be exhibiting at BIO, Chicago, 22-25 April,


Booth #1467.

About Fujifilm Diosynth Biotechnologies (http://www.fujifilmdiosynth.com)


FUJIFILM Diosynth Biotechnologies UK Limited is an industry leading biologics
Contract Development and Manufacturing Organization. Fujifilm Diosynth
Biotechnologies has extensive experience in the development and manufacturing of
recombinant proteins, vaccines, monoclonal antibodies, among other large molecules
expressed in a wide array of microbial, mammalian, and insect systems. The
company offers a comprehensive list of services from microbial and mammalian cell
line development, including its proprietary pAVEway system, to process
development, analytical development, clinical and commercial manufacturing.
Fujifilm Diosynth Biotechnologies is also located in Research Triangle Park, NC, USA
as FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Both sites have been FDA-
approved for the production of commercial biologic products.

About FUJIFILM Holdings Corporation (http://www.fujifilmholdings.com)


FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and
leading-edge products to a broad spectrum of industries, including electronic imaging,
digital printing equipment, medical systems, life sciences, graphic arts, flat panel
display materials, and office products, based on a vast portfolio of digital, optical, fine
chemical and thin film coating technologies. The company was among the top 17
companies around the world granted U.S. patents in 2011, and in the year ended
March 31, 2012, had global revenues of $27.8 billion*. Fujifilm is committed to
environmental stewardship and good corporate citizenship.
* At an exchange rate of 79 yen to the dollar.

Оценить